{"analyses":[{"ciLowerLimit":"64.0","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"151.3","estimateComment":"Ratio of geometric means is calculated as Azacitidine 50 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% confidence interval (CI) of ratio of geometric means are from one way analysis of variance models on the nature log-transformed dose-normalized AUC0-t, obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"98.4"},{"ciLowerLimit":"44.7","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"101.8","estimateComment":"Ratio of geometric means is calculated as Azacitidine 75 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance models on the nature log-transformed dose-normalized AUC0-t, obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"67.5"},{"ciLowerLimit":"53.8","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"127.2","estimateComment":"Ratio of geometric means is calculated as Azacitidine 100 mg/m\\^2 / Azacitidine 25 mg/m\\^2 and expressed as a percentage.","groupDescription":"Geometric means, ratio and 90% CI of ratio of geometric means are from one way analysis of variance models on the nature log-transformed dose-normalized AUC0-t, obtained on Day 1. Azacitidine 25 mg/m\\^2 is the reference group for comparisons","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of Geometric Means","paramValue":"82.7"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.22","value":"454.80"},{"groupId":"OG001","spread":"31.20","value":"895.38"},{"groupId":"OG002","spread":"39.20","value":"920.76"},{"groupId":"OG003","spread":"25.57","value":"1505.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function (defined as creatinine clearance \\> 80 mL/min/1.73m\\^2) received a single subcutaneous dose of azacitidine 25 mg/m\\^2 on Day 1.","id":"OG000","title":"Azacitidine 25 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\\^2 on Day 1.","id":"OG001","title":"Azacitidine 50 mg/m^2"},{"description":"Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\\^2 on Days 1 to 5.","id":"OG002","title":"Azacitidine 75 mg/m^2"},{"description":"Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\\^2 on Day 1.","id":"OG003","title":"Azacitidine 100 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population, consisting of all participants with evaluable plasma or urine concentration data for azacitidine. This analysis was performed for participants with normal renal function only.","reportingStatus":"POSTED","timeFrame":"Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose","title":"Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point","type":"PRIMARY","unitOfMeasure":"ng*hr/mL"}